文献速递泌尿男性生殖肿瘤

局限性前列腺癌中间临床终点的替代性:聚合荟萃分析

Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.
PubMed 文献 · Lancet Oncol · 2021-01-01

BACKGROUND: The international Intermediate Clinical Endpoints in Cancer of the Prostate working group has established metastasis-free survival as a surrogate for overall survival in localised prostate cancer based on the findings of 19 predominantly radiotherapy-based trials.…

要点

  • 无转移生存是唯一被验证的局限性前列腺癌总生存替代终点。
  • 基于生化失败和局部失败的终点不能替代总生存。
  • 无进展生存与总生存仅中等相关,未达替代标准。

核心结论

  • 基于生化失败和局部失败的中间临床终点不满足替代终点条件,不能替代总生存。
  • 无转移生存是迄今唯一被验证的局限性前列腺癌总生存替代终点。

研究设计与样本

  • 聚合荟萃分析,检索PubMed 1970年1月1日至2020年1月15日发表的随机治疗试验。
  • 纳入报告总生存和至少一个中间临床终点、样本量≥70例的局限性或生化复发前列腺癌试验,排除转移性疾病试验。

临床怎么用

  • 在局限性前列腺癌临床试验中,可优先采用无转移生存作为总生存的替代终点。
  • 不应使用基于生化失败或局部失败的中间终点替代总生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The international Intermediate Clinical Endpoints in Cancer of the Prostate working group has established metastasis-free survival as a surrogate for overall survival in localised prostate cancer based on the findings of 19 predominantly radiotherapy-based trials. We sought to comprehensively assess aggregate trial-level performance of commonly reported intermediate clinical endpoints across all randomised trials in localised prostate cancer. METHODS: For this meta-analysis, we searched PubMed for all trials in localised or biochemically recurrent prostate cancer published between Jan 1, 1970, and Jan 15, 2020. Eligible trials had to be randomised, therapeutic, reporting overall survival and at least one intermediate clinical endpoint, and with a sample size of at least 70 participants. Trials of metastatic disease were excluded. Intermediate clinical endpoints included biochemical failure, local failure, distant metastases, biochemical failure-free survival, progression-free survival, and metastasis-free survival. Candidacy for surrogacy was assessed using the second condition of the meta-analytical approach (ie, correlation of the treatment effect of the intermediate clinical endpoint and overall survival), using R2 weighted by the inverse variance of the log intermediate clinical endpoint hazard ratio. The intermediate clinical endpoint was deemed to be a surrogate for overall survival if R2 was 0·7 or greater. FINDINGS: 75 trials (53 631 patients) were included in our analysis. Median follow-up was 9·1 years (IQR 5·7-10·6). Biochemical failure (R2 0·38 [95% CI 0·11-0·64]), biochemical failure-free survival (R2 0·12 [0·0030-0·33]), biochemical failure and clinical failure (R2 0·28 [0·0045-0·65]), and local failure (R2 0·085 [0·00-0·37]) correlated poorly with overall survival. Progression-free survival (R2 0·46 [95% CI 0·22-0·67]) showed moderate correlation with overall survival, and metastasis-free survival (R2 0·78 [0·59-0·89]) correlated strongly. INTERPRETATION: Intermediate clinical endpoints based on biochemical and local failure did not meet the second condition of the meta-analytical approach and are not surrogate endpoints for overall survival in localised prostate cancer. Our findings validate metastasis-free survival as the only identified surrogate endpoint for overall survival to date. FUNDING: Prostate Cancer Foundation and National Institutes of Health.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Gharzai LA, Jiang R, Wallington D, et al. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncol. 2021. PMID: 33662287. doi:10.1016/S1470-2045(20)30730-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。